iBio, Inc.

As of October 15, 2023, iBio, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position compared to peers like Moderna and Novavax.

As of October 1, 2023, there is not enough technical data for iBio, Inc. to determine a bullish or bearish outlook.

As of March 2022, the management team of iBio, Inc. includes Chairman and CEO Thomas Isett, Interim Secretary and Treasurer Robert Kay, and independent directors Linda Armstrong, Glenn Chang, Seymour Flug, Gen. (Retd.) James Hill, and Alexandra Kropotova. They are responsible for the company's governance and strategic direction.

iBio, Inc. is a biotechnology company focused on commercializing technologies and product candidates in the Pharmaceuticals & Biotechnology industry, with a market cap of $13.22 million and a recent net profit of -$5 million. The company has no dividend yield and operates at a loss, reflected in its negative financial metrics.

As of Jun 18, iBio, Inc. has a market capitalization of 13.22 million, classifying it as a Micro Cap company, with net sales of 0.37 million and a net profit of -16.46 million over the latest four quarters. As of Jun 24, the company's shareholder's funds were 21.32 million, and total assets were 28.73 million.